HealthWarehouse.com Reports Results for Third Quarter 2025

Core Viewpoint - HealthWarehouse.com reported a 7% decline in sales for Q3 2025, attributed to slowing direct-to-consumer (DTC) sales and shifts in the GLP-1 market [1][19]. Financial Performance - Net sales for Q3 2025 totaled $8.4 million, a decrease of 7% from $9.0 million in Q3 2024 [1][5]. - Year-to-date sales reached $39.1 million, reflecting a 97% increase compared to $19.9 million in the prior year [1][5]. - The company reported a net loss of $72,000 for Q3 2025, compared to a net income of $74,000 in Q3 2024 [10]. - Adjusted EBITDA for Q3 2025 was $343,000, down from $405,000 in Q3 2024 [11]. Sales Breakdown - Prescription sales were $7.7 million for Q3 2025, a decrease of 7.9% from $8.4 million in Q3 2024 [6]. - Over-the-counter product sales increased by 10.8% to $689,000 in Q3 2025, compared to $622,000 in Q3 2024 [7]. Gross Profit and Margins - Gross profit for Q3 2025 was $3.6 million, a decrease of $194,000 from the previous year [8]. - Gross margin percentages were 42.8% for Q3 2025, slightly higher than the previous year, but lower for the nine-month period at 34.0% [8]. Operating Expenses - Selling, general and administrative expenses were $3.6 million for Q3 2025, a slight increase of 0.1% from the previous year [9]. - Year-to-date operating expenses totaled $12.8 million, an increase of 27.6% compared to $10.0 million in the prior year [9]. Management Commentary - The CEO expressed optimism about future growth despite the current sales slowdown, highlighting a strong pipeline of new opportunities and the company's ability to generate positive cash flow [3][4]. - The company continues to invest in proprietary technology to enhance patient experience and operational efficiency [3].